Formulated.

Formulated for
cost reform.

Cost of cancer care represents a significant financial burden to patients. Price increases have driven up the cost of oncology supportive care.1
Neulasta® (pegfilgrastim) Historical Prices in the US1
Pegfilgrastim WAC
Consumer Price Index*
Wholesale acquisition cost (WAC) has more than doubled since 2006+132%
+27%
Competition
for a change
Competition for a change
A major contributor to the rising cost of care, biologics account for 40% of prescription drug spending in the United States, which reached a record $425 billion in 2015.2 Biosimilars such as UDENYCA® may positively impact patients, providers, and the healthcare system at large.
Benefits of Biosimilars

PROVIDERS2,3
- Provides a choice that has the potential to lower the financial burden
- May help increase patient access

PATIENTS2,3
- Helps decrease overall financial burden
- Increases access to treatment options

SYSTEM2,3
- Offsets the burden of increasing healthcare costs in areas such as oncology
- Potential savings due to more treatment choices and increased competition
- May free up resources for other important aspects of healthcare

PROVIDERS2,3
- Provides a choice that has the potential to lower the financial burden
- May help increase patient access

PATIENTS2,3
- Helps decrease overall financial burden
- Increases access to treatment options

SYSTEM2,3
- Offsets the burden of increasing healthcare costs in areas such as oncology
- Potential savings due to more treatment choices and increased competition
- May free up resources for other important aspects of healthcare
UDENYCA® offers SIGNIFICANT COST SAVINGS for your patients and practice4
Wholesale Acquisition Cost (WAC)
Neulasta®
~$6200
UDENYCA®
$4175
UDENYCA® delivers high-quality treatment and the reliable outcomes that you expect with Neulasta®, but with 32% cost savings
for your patients and practice.4,5
UDENYCA® delivers high-quality treatment and the reliable outcomes that you expect with Neulasta®, but with 32% cost savings for your patients and practice.4,5
References: 1. United States Bureau of Labor Statistics. SHA National Data, MAT. January 2018. 2. Biosimilars: a safe & effective option for patients. The Biosimilars Council. Updated January 2018. Accessed July 22, 2020. http://biosimilarscouncil.org/wp-content/uploads/2017/11/Biosimilars-Fact-Sheet_Updated-10-9-17-Final.pdf 3. Biosimilars overview. Biosimilars Forum. Accessed May 19, 2020. http://www.biosimilarsforum.org/sites/default/files/uploads/biosimilars_overview_032816opt_-_copy_0.pdf 4. First Databank, Inc. Pricing Compendia. 5. UDENYCA® (pegfilgrastim-cbqv) package insert. Redwood City, CA: Coherus BioSciences, Inc.; 2019.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATION:
Patients with a history of serious allergic reaction to human granulocyte colony-stimulating factors such as pegfilgrastim or filgrastim products.
- Fatal splenic rupture: Evaluate patients who report left upper abdominal or shoulder pain for an enlarged spleen or splenic rupture.
- Acute respiratory distress syndrome (ARDS): Evaluate patients who develop fever, lung infiltrates, or respiratory distress. Discontinue UDENYCA® in patients with ARDS.
- Serious allergic reactions, including anaphylaxis: Permanently discontinue UDENYCA® in patients with serious allergic reactions.
- Fatal sickle cell crises: Have occurred.
- Glomerulonephritis: Evaluate and consider dose-reduction or interruption of UDENYCA® if causality is likely.
WARNINGS AND PRECAUTIONS:
ADVERSE REACTIONS:
Most common adverse reactions (≥ 5% difference in incidence compared to placebo) are bone pain and pain in extremity.
To report SUSPECTED ADVERSE REACTIONS, contact Coherus BioSciences at 1-800-4-UDENYCA (1-800-483-3692) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
INDICATION
UDENYCA® is a leukocyte growth factor indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
Limitations of Use
UDENYCA® is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.